Does this patient have a mole or a melanoma?

JAMA

Volumn 279, Issue 9, 1998, Pages 696-701

  Whited, John D ^a,b   Grichnik, James M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER RISK; CARCINOGENESIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; MELANOMA; NEVUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ARTICLE; DERMATOLOGY; HUMAN; MEDICINE; SENSITIVITY AND SPECIFICITY; SKIN PIGMENTATION; SKIN TUMOR;

DERMATOLOGY; HUMANS; MELANOMA; NEVUS; PHYSICAL EXAMINATION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SKIN PIGMENTATION; SPECIALTIES, MEDICAL;

EID: 0032481571     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.9.696     Document Type: Review

References (43)

1. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermotol. 1996;34:839-847.
2. American Academy of Dermatology. Program and Screening Guidelines: National Skin Cancer Prevention Education Program. Schaumburg, III: American Academy of Dermatology; 1996:37.
3. Ries LAG, Hankey BF, Miller BA, Hartman AM, Edwards BK Cancer Statistics Review 1973-1988. Bethesda, Md: National Cancer Institute; 1991.
4. Barnhill RL, Mihm MC Jr, Fitzpatrick TB, Sober AJ. Neoplasms: malignant melanoma. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, eds. Dermatology in General Medicine. 4th ed. New York, NY: McGraw-Hill Inc; 1993:1078-1115.
5. NIH Consensus Development Panel on Early Melanoma. Diagnosis and treatment of early melanoma. JAMA. 1992;268:1314-1319.
6. Day CL Jr, Mihm MC Jr, Lew RA, Kopf AW, Sober AJ, Fitzpatrick TB. Cutaneous malignant melanoma: prognostic guidelines for physicians and patients. Cancer J Clinician. 1982;32:113-122.
7. Koh HK. Cutaneous melanoma. N Engl J Med. 1991;325:171-182.
8. Koh HK, Miller DR, Geller AC, Clapp RW, Mercer MB, Lew RA. Who discovers melanoma: patterns from a population-based survey. J Am Acad Dermatol. 1992;26:914-919.
9. Wick MM, Sober AJ, Fitzpatrick TB, et al. Clinical characteristics of early cutaneous melanoma. Cancer. 1980;45:2684-2686.
10. Keefe M, Dick DC, Wakeel RA. A study of the value of the seven-point checklist in distinguishing benign pigmented lesions from melanoma. Clin Exp Dermatol. 1990;15:167-171.
11. Elwood JM, Gallagher RP. The first signs and symptoms of melanoma: a population-based study. Pigment Cell. 1988;9:118-130.
12. Rigel DS, Friedman RJ, Kopf AW, et al. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol. 1986;14:857-860.
13. Swerdlow AJ, English J, MacKie RM, et al. Benign melanocytic naevi as a risk factor for malignant melanoma. BMJ. 1986;292:1555-1559.
14. Greene MH, Clark WH, Tucker MA, Kraemer KH, Elder DE, Freaser MC. High risk of malignant melanoma in melanoma-prone families with dy splastic nevi. Ann Intern Med. 1985;102:458-465.
15. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dy splastic nevi: a central risk factor for cutaneous melanoma. JAMA 1997;277:1439-1444.
16. Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi: markers for increased risk for melanoma. Cancer. 1989;63:386-389.
17. Tiersten AD, Grin CM, Kopf AW, et al. Prospective follow-up for malignant melanoma in patients with atypical-mole dysplastic-nevus syndrome. J Dermatol Surg Oncol. 1991;17:44-48.
18. Masri GD, Clark WH, Guerry D, Halpern A, Thompson CJ, Elder DE. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol. 1990;22:1042-1048.
19. Titus-Ernstoff L, Ernstoff MS, Kirkwood JM, Barnhill RL, Fine J, Duray PH. Usefulness of frequent skin examination for the early detection of secondary primary cutaneous melanoma. Cancer Detect Prev. 1989;13:317-321.
20. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. Cancer J Clinician. 1985;35:130-151.
21. Fitzpatrick TB, Rhodes AR, Sober AJ, Mihm MC Jr. Primary malignant melanoma of the skin: the call for action to identify persons at risk; to discover precursor lesions; to detect early melanomas. Pigment Cell. 1988;9:110-117.
22. MacKie RM. Clinical recognition of early invasive melanoma. BMJ. 1990;301:1005-1006.
23. Du Vivier AWP, Williams HC, Brett JV, Higgins EM. How do malignant melanomas present and does this correlate with the seven-point check-list? Clin Exp Dermatol. 1991;16:344-347.
24. Higgins EM, Hall P, Todd P, Murhti R, Du Vivier AWP. The application of the seven-point check-list on the assessment of benign pigmented lesions. Clin Exp Dermatol. 1992;17:313-315.
25. Holleman DR, Simel DL. Does the clinical examination predict airflow limitation? JAMA. 1995;273:313-319.
26. Barnhill RL, Roush GC, Ernstoff MS, Kirkwood JM. Interclinician agreement on the recognition of selected gross morphologic features of pigmented lesions: studies of melanocytic nevi V. J Am Acad Dermatol. 1992;26:185-190.
27. Meyer LJ, Piepkorn M, Goldgar DE, et al. Interobserver concordance in discriminating clinical atypia of melanocytic nevi, and correlations with histologic atypia. J Am Acad Dermatol. 1996;34:618-625.
28. Landis JR, Koch GG. The measurement of observer agreement in categorical data. Biometrics. 1977;33:159-174.
29. Healsmith MF, Bourke JF, Osborne JE, Graham-Brown RAC. An evaluation of the revised seven-point checklist for the early diagnosis of cutaneous melanoma. Br J Dermatol. 1994;130:48-50.
30. McGovern TW, Litaker MS. Clinical predictors of malignant pigmented lesions: a comparison of the Glasgow seven-point checklist and the American Cancer Society's ABCDs of pigmented lesions. J Dermatol Surg Oncol. 1992;18:22-26.
31. Shaw HM, McCarthy WH. Small-diameter malignant melanoma: a common diagnosis in New South Wales, Australia. J Am Acad Dermatol. 1992;27:679-682.
32. DeCoste SD, Stern RS. Diagnosis and treatment of nevomelanocytic lesions of the skin: a community-based study. Arch Dermatol. 1993;129:57-62.
33. Grin CM, Kopf AW, Welkovich B, Bart RS, Levenstein MJ. Accuracy in the clinical diagnosis of malignant melanoma. Arch Dermatol. 1990;126:763-766.
34. Koh HK, Caruso A, Gage I, et al. Evaluation of melanoma/skin cancer screening in Massachusetts: preliminary results. Cancer. 1990;65:375-379.
35. McMullan FH, Hubener LF. Malignant melanoma: a statistical review of clinical and histological diagnoses. Arch Dermatol. 1956;74:618-619.
36. Curley RK, Cook MG, Fallowfield ME, Marsden RA. Accuracy in clinically evaluating pigmented lesions. BMJ. 1989;299:16-18.
37. Koh HK, Norton LA, Geller AC, et al. Evaluation of the American Academy of Dermatology's national skin cancer early detection and screening program. J Am Acad Dermatol. 1996;34:971-978.
38. Krol S, Keijser LMT, Van Der Rhee HJ, Welvaart K. Screening for skin cancer in the Netherlands. Acta Derm Venereol. 1991;71:317-321.
39. Gerbert B, Maurer T, Berger T, et al. Primary care physicians as gatekeepers in managed care: primary care physicians' and dermatologists' skills at secondary prevention of skin cancer. Arch Dermatol. 1996;132:1030-1038.
40. Cassileth BR, Clark WH Jr, Lusk EJ. Frederick BE, Thompson CJ, Walsh WP. How well do physicians recognize melanoma and other problem lesions? J Am Acad Dermatol. 1986;14:555-560.
41. Ramsay DL, Fox AB. The ability of primary care physicians to recognize the common dermatoses. Arch Dermatol. 1981;117:620-622.
42. Paine SL, Cockburn J, Noy SM, Marks R. Early detection of skin cancer: knowledge, perceptions, and practices of general practitioners in Victoria. Med J Aust. 1994;161:188-195.
43. McGee R, Elwood M, Sneyd MJ, Williams S, Tilyard M. The recognition and management of melanoma and other skin lesions by general practitioners in New Zealand. N Z Med J. 1994;107:287-290.